Listed

Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 7, 2019 and accepted by EDGAR at Nov 7, 2019, 06:59 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue3 months2019-07-01 to 2019-09-30$3.2mus-gaap:CostOfRevenue
Cost of revenue9 months2019-01-01 to 2019-09-30$7.9mus-gaap:CostOfRevenue
Research and development3 months2019-07-01 to 2019-09-30$10.0mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2019-01-01 to 2019-09-30$35.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2019-07-01 to 2019-09-30$2.6mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2019-01-01 to 2019-09-30$6.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-07-01 to 2019-09-30−$1.5mus-gaap:OperatingIncomeLoss
Operating income9 months2019-01-01 to 2019-09-30−$12.9mus-gaap:OperatingIncomeLoss
Net income3 months2019-07-01 to 2019-09-30−$3.6mus-gaap:NetIncomeLoss
Net income9 months2019-01-01 to 2019-09-30−$18.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-07-01 to 2019-09-30−$0.02us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2019-01-01 to 2019-09-30−$0.13us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2019-01-01 to 2019-09-30−$15.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2019-01-01 to 2019-09-30$599.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-09-30$21.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$40.4mus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$53.7mus-gaap:Assets
Current liabilitiesAt period end2019-09-30$33.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$124.6mus-gaap:Liabilities
Shareholders' equityAt period end2019-09-30−$70.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-19-060804. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.